On the other hand, blarcamesine, a non-selective S1R agonist in clinical development for AD [61], has moderate affinity for the S1R (Ki = 3700 nM) with the highest affinity for the muscarinic M1 receptor (Ki = 500 nM) [62], showing 0.14-fold lower selectivity for the S1R. This evidence concerns the gene TMBIM4 and Alzheimer disease.